Abstract
Parkinsons disease is a neurodegenerative movement disorder caused by a combination of environmental and genetic factors. Recent human genetic studies have identified five genes that are linked to Parkinsons disease (PD): α-synuclein, parkin, UCH-L1, DJ-1 and NR4A2. Among these genes, a variety of mutations in the human parkin locus have been found in many PD cases, both familial and sporadic. Parkin appears to be the most prevalent genetic factor in PD. It encodes for a protein-ubiquitin E3 ligase, whose loss-offunction mutations cause specific degeneration of dopamine (DA) neurons in substantia nigra in human patients. The accumulation of parkin substrates is thought to be the key factor in the selective death of DA neurons. Rapid progress in the identification of these substrates and the generation of genetic animal models has produced a plethora of knowledge about the biological function of parkin and its role in PD. These studies also offer novel pharmacological targets for the development of more selective therapeutic strategies. In this review, I will summarize results from this fast expanding field and discuss their potential implication in the treatment of Parkinsons disease.
Keywords: parkin, synuclein, parkinson's disease, ubiquitination, misfolding, microtubule, dopamine, tubulin
Current Neuropharmacology
Title: Genetic Factors in Parkinsons Disease and Potential Therapeutic Targets
Volume: 1 Issue: 4
Author(s): Jian Feng
Affiliation:
Keywords: parkin, synuclein, parkinson's disease, ubiquitination, misfolding, microtubule, dopamine, tubulin
Abstract: Parkinsons disease is a neurodegenerative movement disorder caused by a combination of environmental and genetic factors. Recent human genetic studies have identified five genes that are linked to Parkinsons disease (PD): α-synuclein, parkin, UCH-L1, DJ-1 and NR4A2. Among these genes, a variety of mutations in the human parkin locus have been found in many PD cases, both familial and sporadic. Parkin appears to be the most prevalent genetic factor in PD. It encodes for a protein-ubiquitin E3 ligase, whose loss-offunction mutations cause specific degeneration of dopamine (DA) neurons in substantia nigra in human patients. The accumulation of parkin substrates is thought to be the key factor in the selective death of DA neurons. Rapid progress in the identification of these substrates and the generation of genetic animal models has produced a plethora of knowledge about the biological function of parkin and its role in PD. These studies also offer novel pharmacological targets for the development of more selective therapeutic strategies. In this review, I will summarize results from this fast expanding field and discuss their potential implication in the treatment of Parkinsons disease.
Export Options
About this article
Cite this article as:
Feng Jian, Genetic Factors in Parkinsons Disease and Potential Therapeutic Targets, Current Neuropharmacology 2003; 1 (4) . https://dx.doi.org/10.2174/1570159033477053
DOI https://dx.doi.org/10.2174/1570159033477053 |
Print ISSN 1570-159X |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6190 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
- Forthcoming Thematic Issues
Related Articles
-
(Pro)renin Receptor as a New Drug Target
Current Pharmaceutical Design Induced Pluripotent Stem Cell-Based Studies of Parkinson's Disease: Challenges and Promises
CNS & Neurological Disorders - Drug Targets Discovery of Dual Orexin Receptor Antagonists (DORAs) for the Treatment of Insomnia
Current Topics in Medicinal Chemistry Microalbuminuria and the Hypertensive Disorders of Pregnancy
Current Hypertension Reviews Carvacrol as a Potential Neuroprotective Agent for Neurological Diseases: A Systematic Review Article
CNS & Neurological Disorders - Drug Targets A Randomized, Placebo-controlled, Triple-blind Study to Determine the Effect of Farlong Ginseng Plus® NotoGinseng Extract on Cholesterol and Blood Pressure
Current Nutraceuticals Dental Stem Cell in Tooth Development and Advances of Adult Dental Stem Cell in Regenerative Therapies
Current Stem Cell Research & Therapy Oxidative Stress, Sarcopenia, Antioxidant Strategies and Exercise: Molecular Aspects
Current Pharmaceutical Design Therapeutic Potential of Cannabinoids in Neurodegenerative Disorders: A Selective Review
Current Pharmaceutical Design Clinical Issues Encountered in the Refeeding of the Patient with Anorexia Nervosa
Current Nutrition & Food Science Psychosocial Factors and Central Sensitivity Syndromes
Current Rheumatology Reviews Computer Simulation of Antimicrobial Peptides
Current Medicinal Chemistry Restoring the Phenotype of Fragile X Syndrome: Insight from the Mouse Model
Current Molecular Medicine The Role of Microbiota and Intestinal Permeability in the Pathophysiology of Autoimmune and Neuroimmune Processes with an Emphasis on Inflammatory Bowel Disease Type 1 Diabetes and Chronic Fatigue Syndrome
Current Pharmaceutical Design The Future of Neuroregenerative Therapy for Parkinson’s Disease
Current Tissue Engineering (Discontinued) Editorial [Hot topic: Parkinsons Disease (Guest Editor: Jurgen Dinges)]
Current Topics in Medicinal Chemistry Targeted Delivery for Neurodegenerative Disorders Using Gene Therapy Vectors: Gene Next Therapeutic Goals
Current Gene Therapy Targeting the Eph System with Peptides and Peptide Conjugates
Current Drug Targets Role of Artificial Intelligence Techniques (Automatic Classifiers) in Molecular Imaging Modalities in Neurodegenerative Diseases
Current Alzheimer Research Homocysteine Level and Mechanisms of Injury in Parkinson's Disease as Related to MTHFR, MTR, and MTHFD1 Genes Polymorphisms and LDopa Treatment
Current Genomics